Axsome Therapeutics has announced that the first patient was enrolled in the ADVANCE-1 Phase 2/3 trial evaluating the effectiveness and safety of its investigative therapy AXS-05 for the treatment of agitation in Alzheimer’s disease patients. Agitation is related to anxiety and is reported by nearly 50 percent of Alzheimer’s patients. It’s…
A poor night’s sleep may increase the levels of proteins associated with Alzheimer’s disease, say researchers, noting that their findings may be especially important for people with chronic sleep disorders. The study by scientists at Stanford University, Washington University School of Medicine in St. Louis and Radboud University Medical Centre in…
Expression of the protein ANK1 (ankyrin repeat domain-containing protein) is four fold higher in the microglia of patients with Alzheimer’s disease (AD). Microglia are a type of immune cell found in the brain and key regulators of the inflammatory cascade typified in early Alzheimer’s development. ANK1 previously has been identified as…
E-Scape Bio, the Gladstone Institutes’ spin-off company working to develop therapies for neurodegenerative disorders such as Alzheimer’s disease, announced that it has raised a total of $63 million in Series A financing from investors. The biotech startup is developing small-molecule drugs that target apoE4, a gene thought to increase the risk…
Prof. Shi-Jiang Li, PhD, is the recipient of the 2017 Alzheimer Award granted every year by the associate editors of the Journal of Alzheimer’s Disease (JAD). Li was singled out for his and his team’s outstanding work published in the journal about a new index called the “characterizing Alzheimer’s…
Researchers fed the antioxidant fisetin, found in strawberries and other fruits and vegetables, to mice for seven months and found that the compound partially protected the animals from age-associated cognitive decline. Fisetin’s effects correlated with the restoration of neuronal function and less brain inflammation. The results, which follows previous work with…
New results from its intepirdine (RVT-101) and nelotanserin research programs on Alzheimer’s disease (AD) and Lewy body dementia will be shared soon, Axovant Sciences announced. The data will be presented at the 2017 Alzheimer’s Association International Conference (AAIC) in London  July 16-20. Intepirdine is a selective antagonist of the…
People at risk for Alzheimer’s disease who spend more time doing moderate-intensity exercise have a healthier level of glucose metabolism in the brain — considered a reflection of how healthy and active the brain really is. In contrast, low-intensity physical activity, such as a slow walk, was not related to brain…
Patients with Alzheimer’s disease who experience delusions and hallucinations are five times more likely to be misdiagnosed than Alzheimer’s patients without psychosis, new research from St. Michael’s Hospital in Toronto, Canada, found. The study, “Determining the impact of…
AgeneBio has received a $750,000 grant from the Alzheimer’s Drug Discovery Foundation (ADDF) to support the development of a novel GABAA discovery program targeting hippocampal overactivity in the brain, which is thought to contribute to neurodegeneration and cognitive decline in Alzheimer’s disease (AD) patients. AgeneBio’s pipeline of therapies is…
Get regular updates to your inbox.